Loading
Amit Oza is a gynaecologic oncologist who led early olaparib and niraparib studies in ovarian cancer.
Amit M. Oza is Head of the Division of Medical Oncology and Hematology and Director of the Cancer Clinical Research Unit at the Princess Margaret Cancer Centre. He is a gynaecologic oncologist known for leading early olaparib and niraparib studies that established PARP inhibition in BRCA-mutant and platinum-sensitive ovarian cancer. His selected paper reports a randomised phase 2 trial of olaparib combined with chemotherapy in recurrent platinum-sensitive ovarian cancer. He now heads medical oncology at Princess Margaret and continues to lead gynaecologic trials in ovarian and endometrial cancer.
| Title | Journal | Year |
|---|---|---|
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial | Lancet Oncology | 2015 |
| SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer | New England Journal of Medicine | 2018 |
Shares PARP, Olaparib, Ovarian cancer.
Shares Niraparib, PARP, Endometrial cancer, Ovarian cancer.
Shares Niraparib, Olaparib, Ovarian cancer.
Shares SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer, PARP, Olaparib, Ovarian cancer.
Shares SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer, Niraparib, Olaparib, Ovarian cancer.
Shares PARP, Olaparib, Ovarian cancer.
Shares Niraparib, Ovarian cancer.
Shares PARP, Olaparib, Endometrial cancer, Ovarian cancer.